J. Hallas

First name
J.
Last name
Hallas
Rivero-Ferrer, E., Olesen, M., Plana, E., Aguado, J., Saigi-Morgui, N., Rubino, A., et al. (2022). Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany. Clin Drug Investig. http://doi.org/10.1007/s40261-022-01120-2
View
Gaist, D., Rodriguez, L. A., Huerta, C., Hallas, J., & Sindrup, S. H. (2001). Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology.
View
Kuiper, J. G., van Herk-Sukel, M. P. P., Castellsague, J., Pottegard, A., Berglind, I. A., Dedman, D., et al. (2018). Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study. Drugs Real World Outcomes. http://doi.org/10.1007/s40801-018-0133-1
View
Margulis, A. V., Linder, M., Arana, A., Pottegard, A., Berglind, I. A., Bui, C. L., et al. (2018). Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom. PLoS One. http://doi.org/10.1371/journal.pone.0204456
View
Castellsague, J., Kuiper, J. G., Pottegard, A., Berglind, A., Dedman, D., Gutierrez, L., et al. (2018). A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study). Clin Epidemiol. http://doi.org/10.2147/clep.s146442
View
Phiri, K., Hallas, J., Linder, M., Margulis, A., Suehs, B., Arana, A., et al. (2021). A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder. Curr Med Res Opin. http://doi.org/10.1080/03007995.2021.1891035
View
Arana, A., Pottegard, A., Kuiper, J. G., Booth, H., Reutfors, J., Calingaert, B., et al. (2021). Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE). Clinical Epidemiology. http://doi.org/https://doi.org/10.2147/CLEP.S331287
View
Hoffman, V., Hallas, J., Linder, M., Margulis, A. V., Suehs, B. T., Arana, A., et al. (2021). Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Saf. http://doi.org/10.1007/s40264-021-01095-7
View